Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients

J Intern Med. 2021 Dec;290(6):1264-1267. doi: 10.1111/joim.13361. Epub 2021 Aug 9.

Abstract

Background: It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients.

Results: A total of 80 SOT recipients completed a two-dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine.

Conclusion: This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination.

Keywords: Covid-19; immune response; solid organ transplant recipient; vaccine.

Publication types

  • Letter

MeSH terms

  • COVID-19 / epidemiology
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / genetics
  • COVID-19 Vaccines / immunology*
  • Humans
  • Immunogenicity, Vaccine / genetics
  • Immunogenicity, Vaccine / immunology*
  • Organ Transplantation
  • RNA, Messenger / genetics
  • RNA, Messenger / immunology*
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology*
  • Transplant Recipients*

Substances

  • COVID-19 Vaccines
  • RNA, Messenger